The tweet was deleted by the author.
But we saved everything 🙂.
Nautilus Biotechnology has announced an opportunity for researchers to access its Voyager platform at no charge during ASHG2026. The company is inviting interested parties to explore either AKT1 or EGFR proteoforms as part of its Iterative Mapping Grant Program.
Applicants can apply using the provided link and are encouraged to visit booth 1425 at the event for further information or inquiries.
View post on X Loading...
Nautilus Biotechnology previously launched a grant program allowing researchers to analyze AKT1 or EGFR proteoforms in oncology studies at no cost, according to company announcements. The firm is also participating in the ARPA-H backed SEEDS consortium to study disease-related protein misfolding mechanisms, as detailed in an earlier update. These initiatives continue Nautilus’s strategy of supporting academic research through funded access to its proteomics technology.